Hims & Hers Health is now offering GRAIL’s Galleri multi-cancer blood test through its digital health platform, expanding access to screening for more than 50 cancer types, including those lacking established protocols.
Labcorp will deploy Roche’s cobas Mass Spec platform in its US labs, marking the first commercial rollout of this fully automated mass spectrometry system to streamline complex diagnostic testing workflows.
AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026.
Peer-reviewed study found 98% concordance between Techcyte's digital workflow and brightfield microscopy in routine clinical laboratory testing.
The collaboration will provide urologists and oncologists nationwide access to AI-powered tools for non-muscle invasive bladder cancer management.
The all-in-one diagnostic platform combines hematology, biochemistry, and immunoassay testing in a single run.
The company's cell analyzer will enable the investigation of 30-plus cellular characteristics to capture key biological insights and support a planned 1,000-person immune profiling study.
Fast, patient-specific blood test results during surgery can help clinicians decide when transfusions are truly needed.Â
The qPCR-based test detects variants that increase risk of severe fluoropyrimidine chemotherapy toxicity.
A 44-metabolite blood test signature identified by Mass General Brigham and Einstein researchers improved type 2 diabetes risk prediction in a study of over 23,000 participants, according to Nature Medicine.
The exsig Mag RapidBead Pro kit features a four-step workflow that reduces extraction time to under 20 minutes.
The BLOODPAC Consortium has released new analytical validation standards for liquid biopsy MRD tests, offering industry-wide protocols for tumor-informed ctDNA assay development, as detailed in JCO Precision Oncology.
The cobas liat system delivers PCR results in 15 minutes, detecting and differentiating between three Bordetella pathogens including whooping cough.
New recommendations address evolving drug landscape and advancing testing technologies since original 2003 guidance.